From the Research
The recommended dosage for Regan (generic name: regorafenib) 5mg oral solution is not directly stated in the provided evidence, but based on the most recent and highest quality study, the dose-escalation strategy starting with 80 mg/day orally is recommended for patients with refractory metastatic colorectal cancer 1. This strategy allows for optimization of regorafenib dosing with comparable activity and a lower incidence of adverse events. The standard dose of 160 mg/day orally for 21 days of a 28-day cycle is also commonly used, but the dose-escalation approach may be preferred to minimize toxicities. Key considerations in dosing regorafenib include the patient's performance status, previous treatments, and potential for adverse events such as hand-foot skin reaction, hypertension, and fatigue. Effective management of these adverse events is crucial to enable patients to stay on treatment and receive the full benefit of regorafenib therapy, as evidenced by studies on patient selection, education, and management 2. It's also important to note that regorafenib has a distinct adverse event profile compared to traditional cytotoxic chemotherapies, and its use should be guided by the latest clinical evidence and guidelines 3. In clinical practice, regorafenib dosing may need to be individualized based on patient factors and response to treatment, highlighting the importance of close monitoring and communication between healthcare providers and patients.